Introduction: Blockade of the CD47/SIRPa axis has emerged as a promising approach to enhance macrophage-mediated anti-tumor activities in cancer immunotherapy. However, the clinical application of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback